CT-011 MAb in DLBCL Patients Following ASCT
NCT00532259
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
72
Enrollment
INDUSTRY
Sponsor class
Conditions
Lymphoma, Large Cell, Diffuse
Lymphoma, Mixed Cell, Diffuse
Primary Mediastinal Large B-Cell Lymphoma
Interventions
DRUG:
CT-011
Sponsor
CureTech Ltd